124 In addition to MRG-201, Viridian Therapeutics has several other miRNA-based drugs, including MRG-106 (Cobomarsen), which targets miR-155 to inhibit tumor development, and MRG-110, which targets microRNA-92 to promote angiogenesis
Under no circumstances are these products intended for human or animal consumption
We offer our patients both month-to-month treatment plans and membership options
The mechanism differs between product types, but in both cases the end result is a reduction in fat cell volume followed by clearance of the resulting material through the bodys lymphatic system
Combining these peptides may enhance their individual properties, leading to more effective tissue repair and recovery
Monthly 1-week protocols, or 8 weeks on/8 weeks off cycles maintaining benefits without continuous use